News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
869,647 Results
Type
Article (87944)
Company Profile (825)
Press Release (780862)
Multimedia
Podcasts (194)
Webinars (28)
Section
Business (233256)
Career Advice (4146)
Deals (39874)
Drug Delivery (150)
Drug Development (91411)
Employer Resources (204)
FDA (18384)
Job Trends (17426)
News (397894)
Policy (39967)
Tag
Academia (3010)
Academic (2)
Accelerated approval (34)
Adcomms (36)
Allergies (145)
Alliances (56981)
ALS (180)
Alzheimer's disease (1786)
Antibody-drug conjugate (ADC) (342)
Approvals (18556)
Artificial intelligence (619)
Autoimmune disease (155)
Automation (35)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (199)
Biotechnology (490)
Bladder cancer (162)
Brain cancer (65)
Breast cancer (653)
Cancer (4975)
Cardiovascular disease (437)
Career advice (3569)
Career pathing (41)
CAR-T (302)
CDC (59)
Celiac Disease (1)
Cell therapy (820)
Cervical cancer (37)
Clinical research (76943)
Collaboration (1776)
Company closure (5)
Compensation (1141)
Complete response letters (70)
COVID-19 (2989)
CRISPR (98)
C-suite (840)
Cystic fibrosis (154)
Data (6188)
Decentralized trials (2)
Denatured (71)
Depression (149)
Diabetes (528)
Diagnostics (7217)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (298)
Drug pricing (221)
Drug shortages (36)
Duchenne muscular dystrophy (234)
Earnings (100075)
Editorial (63)
Employer branding (25)
Employer resources (173)
Events (135012)
Executive appointments (1028)
FDA (21507)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1540)
Gene editing (212)
Generative AI (63)
Gene therapy (662)
GLP-1 (1113)
Government (5437)
Grass and pollen (8)
Guidances (383)
Healthcare (20942)
HIV (60)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (288)
Immuno-oncology (57)
Indications (86)
Infectious disease (3275)
Inflammatory bowel disease (203)
Inflation Reduction Act (17)
Influenza (118)
Intellectual property (242)
Interviews (816)
IPO (17954)
IRA (60)
Job creations (5199)
Job search strategy (2866)
JPM (64)
Kidney cancer (17)
Labor market (91)
Layoffs (659)
Leadership (40)
Legal (10159)
Liver cancer (98)
Longevity (14)
Lung cancer (676)
Lymphoma (374)
Machine learning (44)
Management (66)
Manufacturing (832)
MASH (172)
Medical device (15014)
Medtech (15061)
Mergers & acquisitions (22968)
Metabolic disorders (1376)
Multiple sclerosis (160)
NASH (23)
Neurodegenerative disease (349)
Neuropsychiatric disorders (95)
Neuroscience (3086)
Neurotech (1)
NextGen: Class of 2026 (7707)
Non-profit (5110)
Now hiring (64)
Obesity (663)
Opinion (333)
Ovarian cancer (165)
Pain (202)
Pancreatic cancer (229)
Parkinson's disease (293)
Partnered (39)
Patents (496)
Patient recruitment (465)
Peanut (60)
People (66852)
Pharmaceutical (145)
Pharmacy benefit managers (32)
Phase I (23781)
Phase II (33380)
Phase III (25167)
Pipeline (4820)
Policy (332)
Postmarket research (3554)
Preclinical (10688)
Press Release (72)
Prostate cancer (241)
Psychedelics (53)
Radiopharmaceuticals (298)
Rare diseases (880)
Real estate (7439)
Recruiting (80)
Regulatory (28931)
Reports (66)
Research institute (2722)
Resumes & cover letters (651)
Rett syndrome (27)
RNA editing (20)
RSV (83)
Schizophrenia (157)
Series A (256)
Series B (194)
Service/supplier (30)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (176)
Sponsored (48)
Startups (4333)
State (2)
Stomach cancer (20)
Supply chain (112)
Tariffs (99)
The Weekly (121)
Vaccines (1139)
Venture capital (94)
Weight loss (457)
Women's health (85)
Worklife (21)
Date
Today (3)
Last 7 days (390)
Last 30 days (2061)
Last 365 days (32938)
2026 (1958)
2025 (33228)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1290)
Alabama (88)
Alaska (7)
Arizona (340)
Arkansas (14)
Asia (51520)
Australia (9045)
California (11409)
Canada (3285)
China (1147)
Colorado (484)
Connecticut (496)
Delaware (343)
Europe (118360)
Florida (1667)
Georgia (368)
Hawaii (3)
Idaho (68)
Illinois (956)
India (66)
Indiana (540)
Iowa (24)
Japan (418)
Kansas (133)
Kentucky (42)
Louisiana (29)
Maine (83)
Maryland (1447)
Massachusetts (8423)
Michigan (354)
Minnesota (662)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (29)
Nevada (124)
New Hampshire (85)
New Jersey (3079)
New Mexico (33)
New York (3021)
North Carolina (1594)
North Dakota (10)
Northern California (5446)
Ohio (349)
Oklahoma (22)
Oregon (54)
Pennsylvania (2286)
Puerto Rico (21)
Rhode Island (50)
South America (1658)
South Carolina (64)
South Dakota (1)
Southern California (4398)
Tennessee (174)
Texas (1802)
United States (41245)
Utah (342)
Vermont (1)
Virginia (285)
Washington D.C. (87)
Washington State (960)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
There are 869,647 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Parkinson’s disease
5 Investigational Therapies That Could Change the Parkinson’s Landscape
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
January 26, 2026
·
9 min read
·
Tristan Manalac
Rare diseases
Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
January 26, 2026
·
7 min read
·
Heather McKenzie
Opinion
To Accelerate Rare Disease Progress, Take a Sandbox Approach
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
January 26, 2026
·
5 min read
·
Oxana Iliach
Press Releases
TempraMed Launches New Product “VIVI Med(TM),” Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channel
January 23, 2026
·
6 min read
Press Releases
SpectronRx Accelerates Commercial Growth with Major Expansion of Its Grissom Aeroplex Manufacturing Campus
The 34-acre site now supports 200,000 square feet of GMP radiopharmaceutical production, with scalable capacity exceeding one million square feet
January 23, 2026
·
1 min read
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”
January 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
MustGrow Closes $2.0 Million Non-Brokered LIFE Offering
January 23, 2026
·
5 min read
Press Releases
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
January 23, 2026
·
6 min read
Government
Spending Bill Clears House, Keeping Priority Review Voucher Hopes Alive
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
January 23, 2026
·
3 min read
·
Tristan Manalac
Rare diseases
Rare Disease Vouchers Caught in Political Abyss. It Didn’t Have To Be This Way
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
January 23, 2026
·
3 min read
·
Heather McKenzie
1 of 86,965
Next
